Urinary tract infections (UTIs) are common within women, and more than 40% of women experience recurrent UTIs (rUTIs). With antibiotic resistance becoming a growing concern, new prevention methods are necessary. 

In the editorial, Dr. De Nisco argues that existing evidence on D-Mannose is incomplete. She cites previously conducted randomized placebo-controlled trials that yielded conflicting results with respect to the efficacy of D-Mannose, noting that limitations of these studies included small sample sizes, varying study criteria, compliance differences, shortened follow-up time, and different outcome measures.

Dr. De Nisco argues that we cannot yet rule out D-Mannose based on the limited available information. She calls for more rigorous investigation, including identifying subpopulations who may reap the most benefits from this treatment and exploring mechanisms of action for D-Mannose in humans. Until further investigation is carried out, we should not rule out the potential of D-Mannose as a low-risk intervention to decrease the likelihood of rUTIs.